The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course Export

@article{citeulike:4531665, abstract = {Although cytogenetic abnormalities are important prognostic factors in myeloid malignancies, they are not included in current prognostic scores for primary myelofibrosis (PMF). To determine their relevance in PMF, we retrospectively examined the impact of cytogenetic abnormalities and karyotypic evolution on the outcome of 256 patients. Baseline cytogenetic status impacted significantly on survival: patients with favorable abnormalities (sole deletions in 13q or 20q, or trisomy 9 {+/-} one other abnormality) had survivals similar to those with normal diploid karyotypes (median, 63 and 46 months, respectively), whereas patients with unfavorable abnormalities (rearrangement of chromosome 5 or 7, or [\≥] 3 abnormalities) had a poor median survival of 15 months. Patients with abnormalities of chromosome 17 had a median survival of only 5 months. A model containing karyotypic abnormalities, hemoglobin, platelet count, and performance status effectively risk-stratified patients at initial evaluation. Among 73 patients assessable for clonal evolution during stable chronic phase, those who developed unfavorable or chromosome 17 abnormalities had median survivals of 18 and 9 months, respectively, suggesting the potential role of cytogenetics as a risk factor applicable at any time in the disease course. Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prospectively evaluated. 10.1182/blood-2008-09-178541}, author = {Tam, Constantine S. and Abruzzo, Lynne V. and Lin, Katherine I. and Cortes, Jorge and Lynn, Alice and Keating, Michael J. and Thomas, Deborah A. and Pierce, Sherry and Kantarjian, Hagop and Verstovsek, Srdan}, citeulike-article-id = {4531665}, citeulike-linkout-0 = {http://dx.doi.org/10.1182/blood-2008-09-178541}, citeulike-linkout-1 = {http://bloodjournal.hematologylibrary.org/cgi/content/abstract/113/18/4171}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/19131547}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=19131547}, day = {30}, doi = {10.1182/blood-2008-09-178541}, journal = {Blood}, keywords = {myelofibrosis}, month = {April}, number = {18}, pages = {4171--4178}, posted-at = {2009-05-17 14:48:31}, priority = {2}, title = {The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course}, url = {http://dx.doi.org/10.1182/blood-2008-09-178541}, volume = {113}, year = {2009} }

TY - JOUR ID - citeulike:4531665 L3 - citeulike-article-id:4531665 N2 - Although cytogenetic abnormalities are important prognostic factors in myeloid malignancies, they are not included in current prognostic scores for primary myelofibrosis (PMF). To determine their relevance in PMF, we retrospectively examined the impact of cytogenetic abnormalities and karyotypic evolution on the outcome of 256 patients. Baseline cytogenetic status impacted significantly on survival: patients with favorable abnormalities (sole deletions in 13q or 20q, or trisomy 9 {+/-} one other abnormality) had survivals similar to those with normal diploid karyotypes (median, 63 and 46 months, respectively), whereas patients with unfavorable abnormalities (rearrangement of chromosome 5 or 7, or [≥] 3 abnormalities) had a poor median survival of 15 months. Patients with abnormalities of chromosome 17 had a median survival of only 5 months. A model containing karyotypic abnormalities, hemoglobin, platelet count, and performance status effectively risk-stratified patients at initial evaluation. Among 73 patients assessable for clonal evolution during stable chronic phase, those who developed unfavorable or chromosome 17 abnormalities had median survivals of 18 and 9 months, respectively, suggesting the potential role of cytogenetics as a risk factor applicable at any time in the disease course. Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prospectively evaluated. 10.1182/blood-2008-09-178541 IS - 18 JF - Blood EP - 4178 TI - The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course VL - 113 SP - 4171 KW - myelofibrosis AU - Tam, Constantine AU - Abruzzo, Lynne AU - Lin, Katherine AU - Cortes, Jorge AU - Lynn, Alice AU - Keating, Michael AU - Thomas, Deborah AU - Pierce, Sherry AU - Kantarjian, Hagop AU - Verstovsek, Srdan PY - 2009/04/30/ UR - http://dx.doi.org/10.1182/blood-2008-09-178541 ER -